Gebhard, C.
Maafi, F.
Stähli, B. E.
Dang, J.
Nachar, W.
de Oliveira Moraes, A. B.
Kernaleguen, A. E.
Lavoie, V.
Mecteau, M.
Mihalache-Avram, T.
Shi, Y.
Chabot-Blanchet, M.
Busseuil, D.
Rhainds, D.
Rhéaume, E.
Tardif, Jean-Claude
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P3SMP3_151740, 1142741)
Novartis Stiftung für Medizinisch-Biologische Forschung
Gottfried und Julia Bangerter-Rhyner-Stiftung
Article History
Received: 16 February 2018
Revised: 26 May 2018
Accepted: 12 June 2018
First Online: 18 June 2018
Compliance with ethical standards
:
: Dr. Tardif has received research grants from Amarin, AstraZeneca, DalCor, Esperion, Ionis, Merck, Pfizer, Sanofi, and Servier; received honoraria from DalCor, Pfizer, Sanofi, and Servier; and holds minor equity interest in DalCor. The other authors report no conflict of interest. Dr Gebhard and Dr Stähli have received research grants from the Novartis Foundation, Switzerland.